{"doi":"10.1016/j.cllc.2016.11.015","title":"Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis","abstract":null,"journal":"Clinical Lung Cancer","year":2017,"id":590848,"datarank":0.8882885044960991,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"self_citation_contribution":0.44166584687496613,"citation_network_contribution":0.446622657621133,"self_endowment_contribution":0.44166584687496613,"citer_contribution":0.446622657621133,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":17,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1393891,"name":"Yutaka Fujiwara","orcid":"0000-0001-6981-0800","position":1,"is_corresponding":false},{"id":1511649,"name":"Kota Itahashi","orcid":null,"position":2,"is_corresponding":false},{"id":1511650,"name":"Shinsuke Kitahara","orcid":null,"position":3,"is_corresponding":false},{"id":133859,"name":"Yasushi Goto","orcid":null,"position":4,"is_corresponding":false},{"id":227924,"name":"Hidehito Horinouchi","orcid":"0000-0001-9090-801X","position":5,"is_corresponding":false},{"id":133857,"name":"Shintaro Kanda","orcid":"0000-0001-7864-3928","position":6,"is_corresponding":false},{"id":133862,"name":"Hiroshi Nokihara","orcid":null,"position":7,"is_corresponding":false},{"id":788866,"name":"Noboru Yamamoto","orcid":"0000-0002-0787-2851","position":8,"is_corresponding":false},{"id":623951,"name":"Kazuhisa Takahashi","orcid":"0000-0001-5749-4118","position":9,"is_corresponding":false},{"id":545853,"name":"Yuichiro Ohe","orcid":"0000-0002-6137-073X","position":10,"is_corresponding":false},{"id":1032137,"name":"Tetsuhiko Asao","orcid":"0000-0002-9975-2282","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis","abstract":"<h4>Background</h4>Second-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). An optimal strategy for using 2 or more ALK inhibitors has not been established. We sought to investigate the clinical impact of sequential use of ALK inhibitors on these tumors in clinical practice.<h4>Patients and methods</h4>Patients with ALK-rearranged NSCLC treated from May 2010 to January 2016 at the National Cancer Center Hospital were identified, and their outcomes were evaluated retrospectively.<h4>Results</h4>Fifty-nine patients with ALK-rearranged NSCLC had been treated and 37 cases were assessable. Twenty-six received crizotinib, 21 received alectinib, and 13 (35.1%) received crizotinib followed by alectinib. Response rates and median progression-free survival (PFS) on crizotinib and alectinib (after crizotinib failure) were 53.8% (95% confidence interval [CI], 26.7%-80.9%) and 38.4% (95% CI, 12.0%-64.9%), and 10.7 (95% CI, 5.3-14.7) months and 16.6 (95% CI, 2.9-not calculable), respectively. The median PFS of patients on sequential therapy was 35.2 months (95% CI, 12.7 months-not calculable). The 5-year survival rate of ALK-rearranged patients who received 2 sequential ALK inhibitors from diagnosis was 77.8% (95% CI, 36.5%-94.0%).<h4>Conclusion</h4>The combined PFS and 5-year survival rates in patients who received sequential ALK inhibitors were encouraging. Making full use of multiple ALK inhibitors might be important to prolonging survival in patients with ALK-rearranged NSCLC.","is_dataset_classified":null,"base_score":2.9444389791664403,"endowment":2.9444389791664403,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28065466","pmcid":null,"openalex_id":"https://openalex.org/W2560284840","authors":[],"funders":[],"total_grants":0,"fwci":1.4071,"citation_percentile":0.83271524,"influential_citations":0,"citation_trend":[{"year":2018,"count":1},{"year":2019,"count":5},{"year":2020,"count":3},{"year":2021,"count":5},{"year":2022,"count":3},{"year":2026,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1525730416303692?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1525730416303692?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.cllc.2016.11.015","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28065466","host_type":"repository"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","Cancer Immunotherapy and Biomarkers","Adult","Aged","Anaplastic Lymphoma Kinase","Antineoplastic Combined Chemotherapy Protocols","Carbazoles","Carcinoma, Non-Small-Cell Lung","Crizotinib","Female","Follow-Up Studies","Humans","Japan","Lung Neoplasms","Male","Middle Aged","Neoplasm Staging","Oncogene Proteins, Fusion","Piperidines","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Retrospective Studies","Survival Analysis"],"mesh_terms":["Crizotinib","Anaplastic Lymphoma Kinase","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Carbazoles","Carcinoma, Non-Small-Cell Lung","Female","Follow-Up Studies","Humans","Japan","Lung Neoplasms","Male","Middle Aged","Neoplasm Staging","Piperidines","Pyrazoles","Pyridines","Retrospective Studies","Oncogene Proteins, Fusion","Survival Analysis","Receptor Protein-Tyrosine Kinases"],"keywords":["Crizotinib","Alectinib","Anaplastic lymphoma kinase","Medicine","Ceritinib","Lung cancer","Internal medicine","ALK inhibitor","Oncology","Gastroenterology","Combined Pfs"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-25T12:41:53.467848Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}